|
|
Volumn 41, Issue 5, 2002, Pages 759-761
|
|
Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: The development of a highly potent prodrug
a
|
|
Author keywords
ADEPT; Antitumor agents; Enzymes; Glycosides; Monoclonal antibodies; Prodrugs
|
|
Indexed keywords
SELECTIVE TREATMENTS;
ANTIBODIES;
BIOLOGICAL ORGANS;
DRUG PRODUCTS;
DRUG THERAPY;
TISSUE;
ONCOLOGY;
ANTIBODY;
ANTINEOPLASTIC AGENT;
ENZYME;
PRODRUG;
RACHELMYCIN;
RACHELMYCIN DERIVATIVE;
1,2,9,9A TETRAHYDROCYCLOPROPA(C)BENZ(E)INDOL 4 ONE;
1,2,9,9A-TETRAHYDROCYCLOPROPA(C)BENZ(E)INDOL-4-ONE;
ANTIBODY CONJUGATE;
BETA GALACTOSIDASE;
CYCLOPROPANE DERIVATIVE;
GALACTOSIDE;
INDOLE DERIVATIVE;
ANIMAL CELL;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CANCER CHEMOTHERAPY;
CONTROLLED STUDY;
DRUG ACTIVITY;
DRUG POTENCY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
DRUG TARGETING;
IC 50;
LUNG CARCINOMA;
NONHUMAN;
SCID MOUSE;
STRUCTURE ACTIVITY RELATION;
ANIMAL;
BRONCHUS TUMOR;
CELL CULTURE;
CELL DIVISION;
CHEMISTRY;
DRUG EFFECT;
FEMALE;
HUMAN;
MALE;
MOUSE;
MOUSE MUTANT;
NEOPLASM;
PANCREAS CARCINOMA;
PATHOLOGY;
ANIMALS;
BETA-GALACTOSIDASE;
BRONCHIAL NEOPLASMS;
CARCINOMA, PANCREATIC DUCTAL;
CELL DIVISION;
CYCLOPROPANES;
ENZYMES;
FEMALE;
GALACTOSIDES;
HUMANS;
IMMUNOCONJUGATES;
INDOLES;
INHIBITORY CONCENTRATION 50;
MALE;
MICE;
MICE, SCID;
NEOPLASMS;
PRODRUGS;
TUMOR CELLS, CULTURED;
|
|
EID: 0036495569
PISSN: 14337851
EISSN: None
Source Type: Journal
DOI: 10.1002/1521-3773(20020301)41:5<759::AID-ANIE759>3.0.CO;2-7 Document Type: Article |
|
Times cited : (48)
|
|
References (32)
|
